Recordati acquires EUSA Pharma and its 4 rare disease drugs, but analysts question strategy behind the deal
An Italian pharma company engineered a nearly $850 million buyout last week looking to expand its rare disease portfolio and further soak up parts of the US market, but questions remain over the drugs involved and when they could see patient uptake stateside.
Recordati shelled out the cash to acquire EUSA Pharma and its portfolio of four rare disease drugs, the companies announced Friday, allowing Recordati to position itself — by its own account — for growth in the US. EUSA’s top candidate for expansion is ostensibly the neuroblastoma drug Qarziba, approved in the EU for high-risk, newly-diagnosed individuals.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters